Title Page
Contents
Abstract 5
List of Abbreviation 10
Introduction 11
Materials and methods 14
Results. 18
Discussion 22
Reference 29
Appendix. IRB(Institutional Review Board) approval 43
국문 초록 45
Table 1. Baseline characteristics (n=194). Data are presented as numbers of participants or mean ± standard deviation. 33
Table 2. Comparison of doses and coefficients of variation between the two groups. Data are presented as mean ± standard deviation. 34
Table 3. Comparison of pharmacodynamics parameters and coefficients of variation between the two groups. Data are presented as mean ± standard deviation. 35
Figure 1. Comparison of the doses of warfarin in the powder (○) and tablet (■) groups for 7days. 36
Figure 2. Comparison of the BSA normalised of dose of warfarin in the powder (○) and tablet (■) groups for 7days.... 37
Figure 3. Comparison of the INR of warfarin in the powder (○) and tablet (■) groups for 7days.... 38
Figure 4. Comparison of the dose normalised of international normalized ratio (INR) of warfarin in the powder (○) and tablet (■) groups for... 39
Figure 5. Comparison of the body surface area (BSA) normalised of international normalized ratio (INR) of warfarin in the powder (○) and... 40
Figure 6. Comparison of the warfarin sensitivity index (WSI) in the powder (○) and tablet (■) groups for 7days. 41
Figure 7. Survival curve of time to reach plasma warfarin concentration that can induce adverse effects such as bleeding for 7days(median... 42